Robot-assisted laparoscopic partial nephrectomy is increasingly being favored for treatment of small renal cortical neoplasms. The technique utilized varies based upon the institution and surgeon experience and several modifications have been proposed. We choose to utilize the fourth robotic arm as well as the Satinsky vascular clamp for these cases. Previously, we would utilize the fourth arm through a robotic port until the hilum was dissected, then replace the trocar with a flexible trocar for the Satinski clamp. We now utilize a hybrid-port technique where we establish placement of the flexible trocar and pass a robotic trocar through this to begin with the fourth arm in use. We then remove the fourth arm and the trocar after the hilum is dissected to place the Satinski clamp. The technique and description will be discussed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11701-011-0318-z | DOI Listing |
Front Immunol
December 2024
Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Background: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G protein-coupled receptor, class C group 5 member D (GPRC5D) to treat relapsed or refractory multiple myeloma (RRMM). In this study, we compared the efficacy and safety of BCMA CAR-T-cell therapy (BCMA CAR-T) and GPRC5D CAR T-cell therapy (GPRC5D CAR-T) in patients with RRMM.
Methods: We retrieved and included eligible clinical trials of BCMA or GPRC5D CAR-T for RRMM patients.
Cureus
December 2024
Student Research Unit, School of Medicine, 21 September University, Sana'a, YEM.
Penetrating thoracic injuries, especially those affecting cardiac structures, are rare but can be life-threatening, requiring urgent medical care. Right atrium injuries pose significant risks, including rapid blood loss, cardiac tamponade, hemodynamic instability, and, subsequently, potential death. We report the case of a 24-year-old male patient with stab wounds leading to a right-sided chest penetration three hours prior to presentation.
View Article and Find Full Text PDFCancer
January 2025
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Introduction: The prognosis of relapsed or refractory mature T- and natural killer (NK)-cell lymphoma remains dismal. Novel agents are urgently needed to improve the outcomes for this population.
Methods: In this phase 2, multicenter, open-label, single-arm study (NCT03776279), the authors report the efficacy and safety of liposomal mitoxantrone (Lipo-MIT) monotherapy in patients with relapsed or refractory mature T- and NK-cell lymphoma.
Biol Direct
December 2024
Urology Unit, Department of Surgery, Tor Vergata University of Rome, Rome, Italy.
Background: Prostate cancer is the most common diagnosed tumor and the fifth cancer related death among men in Europe. Although several genetic alterations such as ERG-TMPRSS2 fusion, MYC amplification, PTEN deletion and mutations in p53 and BRCA2 genes play a key role in the pathogenesis of prostate cancer, specific gene alteration signature that could distinguish indolent from aggressive prostate cancer or may aid in patient stratification for prognosis and/or clinical management of patients with prostate cancer is still missing. Therefore, here, by a multi-omics approach we describe a prostate cancer carrying the fusion of TMPRSS2 with ERG gene and deletion of 16q chromosome arm.
View Article and Find Full Text PDFUpdates Surg
December 2024
Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, Sichuan, China.
Gastric cancer, as the fifth most diagnosed malignancy and the fourth leading cause of cancer-related death globally, remains a significant health concern. The potential effect of the programmed death-1 (PD-1) inhibitor, when used alongside chemotherapy and antiangiogenic agents in neoadjuvant therapy for gastric cancer, has yet to be explored in the published literature. This study aims to evaluate the efficacy and safety of the S-1 plus oxaliplatin (SOX) regimen when combined with apatinib and camrelizumab (SOXAC) as neoadjuvant therapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!